Oncology

A recent study published in CANCER indicates that for patients with both HIV and cancer, implementation of the Patient Protection and Affordable Care Act (ACA) improved insurance coverage, both in states that expanded Medicaid coverage and in states that did not.1

Weight loss surgery found to cut the overall risk of developing cancers linked to obesity by 20%.

FDA breakthrough designation is based on data for nivolumab plus ipilimumab in a study evaluating the immuno-oncology combination in patients with advanced hepatocellular carcinoma previously treated with sorafenib.

Rituximab-abbs (Truxima, Teva and Celltrion), has been launched in the United States with a full oncology label for non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Pegfilgrastim-bmez (Ziextenzo, Sandoz), a biosimilar to pegfilgrastim (Neulasta), is indicated to decrease the incidence of febrile neutropenia, a serious adverse effect of chemotherapy.

The largest ever trial of postoperative radiotherapy in prostate cancer shows men may be spared the procedure after surgery.

Top news of the day from across the health care landscape

Men treated with stereotactic ablative radiotherapy found to live significantly longer without any detectable disease progression compared with patients who received no additional treatment.

A study assessing melanoma cell variability indicates that identifying differences in cell states can be leveraged to improve patient outcomes.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Psoriasis may increase the risk of cancer incidence and cancer-related mortality in affected individuals.

Genentech has announced the results of a Phase III study which showed that atezolizumab (Tecentriq) in combination with bevacizumab (Avastin) increased overall survival and progression-free survival in patients with unresectable hepatocellular carcinoma (HCC).

Patients with metastatic breast cancer who receive care aligned with National Comprehensive Cancer Network guidelines experienced less financial burden than patients who received guideline-discordant treatment.

Niraparib (Zejula) received approval for patients with advanced homologous recombination deficiency-positive status ovarian cancer who have received 3 or more prior chemotherapies.

Top news of the day from across the health care landscape.

In addition to Jennifer Garner, actresses Julia Louis-Dreyfus and Christina Applegate are advocates for breast cancer, both being survivors of the disease.

Researchers note that a metabolic imbalance in some patients with cancer following treatment with nivolumab is associated with shorter survival.

Pegilodecakin in combination with pembrolizumab and nivolumab achieved measurable responses in patients with non-small cell lung cancer and kidney cancer.

Top news of the day from across the health care landscape.

After participating in a sleep-education program, 41% of participants who survived cancer had their insomnia successfully treated.

Top news of the week from Specialty Pharmacy Times.

Glenmark Pharmaceuticals has received FDA approval for abiraterone acetate tablets USP, 250 mg, a generic of Janssen's Zytiga tablets, 250 mg.1

Study suggests that blocking a signaling pathway that includes the inflammatory factor CXCL10-CXCR3 may prevent brain metastasis.

The full-day meeting will feature recognized experts sharing the latest clinical data in oncology, while exploring best practices and management strategies.

Expanded access to direct-acting antiviral drugs are vital to achieve elimination targets set by the World Health Organization for hepatitis C virus infections.

This article is the third in a series on difficult to pronounce drug names.

Ramucirumab (Cyramza) in combination with erlotinib delayed disease progression in previously untreated patients with EGFR-mutated non-small cell lung cancer.

Study finds health-related quality of life is often not collected for novel cancer drugs when they are submitted for reimbursement.